Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer

Br J Cancer. 1992 Nov;66(5):981-3. doi: 10.1038/bjc.1992.396.

Authors

B Fiorentino¹, P Di Stefano, C Giuliani, C Amatetti, N Tinari, C Natoli, C Garufi, S Iacobelli

Affiliation

¹ Cattedra di Oncologia Medica, Chieti, Italy.

No abstract available

Publication types

Clinical Trial

MeSH terms

Adjuvants, Immunologic / therapeutic use
Adult
Aged
Carcinoma, Renal Cell / drug therapy
Carcinoma, Renal Cell / immunology
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Eye Neoplasms / drug therapy
Eye Neoplasms / immunology
Female
Humans
Immunity, Cellular / drug effects
Injections, Intramuscular
Interferon alpha-2
Interferon-alpha / adverse effects
Interferon-alpha / therapeutic use*
Interleukin-2 / adverse effects
Interleukin-2 / therapeutic use*
Kidney Neoplasms / drug therapy
Kidney Neoplasms / immunology
Killer Cells, Lymphokine-Activated / drug effects
Killer Cells, Lymphokine-Activated / immunology
Killer Cells, Natural / drug effects
Killer Cells, Natural / immunology
Male
Melanoma / drug therapy
Melanoma / immunology
Middle Aged
Neoplasms / immunology*
Neoplasms / therapy*
Recombinant Proteins

Substances

Adjuvants, Immunologic
Interferon alpha-2
Interferon-alpha
Interleukin-2
Recombinant Proteins